List of Excipients in Branded Drug PANRETIN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Advanz Pharma (US) Corp	PANRETIN	alitretinoin	59212-601	ALCOHOL
Advanz Pharma (US) Corp	PANRETIN	alitretinoin	59212-601	BUTYLATED HYDROXYTOLUENE
Advanz Pharma (US) Corp	PANRETIN	alitretinoin	59212-601	HYDROXYPROPYL CELLULOSE
Advanz Pharma (US) Corp	PANRETIN	alitretinoin	59212-601	POLYETHYLENE GLYCOL 400
Eisai Inc	PANRETIN	alitretinoin	62856-601	ALCOHOL
Eisai Inc	PANRETIN	alitretinoin	62856-601	BUTYLATED HYDROXYTOLUENE

PANRETIN Excipient Strategy and Commercial Opportunities for Alitretinoin Gel

Last updated: August 27, 2026

PANRETIN is a topical 0.1% alitretinoin gel approved by the U.S. Food and Drug Administration for the topical treatment of cutaneous lesions associated with AIDS-related Kaposi’s sarcoma. Its excipient system is relatively simple: carbomer 934P, isopropyl myristate, mineral oil, polyethylene glycol 400, purified water, and tromethamine. The commercial opportunity is therefore less likely to come from a conventional “same gel, lower price” generic and more likely to come from improved tolerability, controlled delivery, packaging, and access to a small orphan oncology market.[1]

U.S. small-molecule exclusivity and the principal historical patent barriers have expired. PANRETIN is not a biologic, so biosimilar regulation does not apply. The principal development routes are an abbreviated new drug application for a therapeutically equivalent gel, a 505(b)(2) application for a differentiated topical formulation, or a nonprescription and specialty-care strategy only if the sponsor can overcome the product’s prescription status, local irritation profile, and limited addressable market.

What is PANRETIN and which excipients does it contain?

PANRETIN contains alitretinoin, also known as 9-cis-retinoic acid, at a concentration of 0.1% in a topical gel. The FDA-approved product is indicated for the topical treatment of cutaneous lesions in patients with AIDS-related Kaposi’s sarcoma when lesions are not appropriate for systemic therapy or injectable treatment.[1]

Product attribute	PANRETIN profile
Active ingredient	Alitretinoin, 9-cis-retinoic acid
Strength	0.1% topical gel
Dosage form	Topical gel
U.S. sponsor historically associated with product	Eisai Inc.
FDA pathway	505(b)(1) NDA
Therapeutic area	AIDS-related cutaneous Kaposi’s sarcoma
Key route of competition	ANDA generic or differentiated 505(b)(2) topical product
Biosimilar exposure	None
Principal formulation issue	Local irritation and variable patient tolerability

The labeled inactive ingredients are carbomer 934P, isopropyl myristate, mineral oil, polyethylene glycol 400, purified water, and tromethamine.[1] The formulation combines a carbomer gel structure with an emollient oil phase and a penetration-supporting ester. Tromethamine adjusts pH and neutralizes the carbomer sufficiently to produce the target gel viscosity.

How does the PANRETIN excipient system work?

The PANRETIN vehicle performs four principal functions:

1. Carbomer 934P creates the semisolid gel matrix.
2. Tromethamine neutralizes the carbomer and controls gel development and pH.
3. Isopropyl myristate supports spreading and may enhance skin penetration.
4. Mineral oil and polyethylene glycol 400 contribute emollience, wetting, and drug distribution within the vehicle.

Alitretinoin is highly lipophilic and chemically sensitive. The vehicle must maintain drug uniformity while controlling precipitation, oxidation, light exposure, and delivery into the target skin layers. A formulation that increases penetration without controlling irritation could reduce practical adherence even if it improves in vitro delivery.

What excipients are most important for a PANRETIN generic?

The highest-value excipient decisions concern the carbomer system, oil phase, cosolvent balance, pH, and packaging. A generic applicant does not need to copy every inactive ingredient, but it must demonstrate pharmaceutical equivalence and bioequivalence under the applicable FDA requirements.[2]

Carbomer 934P

Carbomer 934P supplies viscosity and helps keep alitretinoin distributed throughout the gel. The grade, concentration, neutralization level, and mixing process influence:

• Yield stress and spreadability
• Drug sedimentation or crystallization
• Extrudability from the tube
• Residence time on the lesion
• Skin feel after application
• Water loss during storage

A formulation with lower viscosity may spread more easily but run off lesions and provide shorter residence time. A higher-viscosity gel may improve retention while increasing tack and patient discomfort.

Tromethamine

Tromethamine controls carbomer neutralization and final pH. Small changes can alter viscosity, drug solubility, chemical stability, and skin tolerability. For alitretinoin, the pH target is a critical quality attribute because retinoids can undergo degradation through oxidation and light-mediated pathways.

A generic formulation should control pH tightly across the shelf life rather than only at release. The sponsor should evaluate pH drift after repeated tube opening, because water loss and environmental exposure can change gel properties in use.

Isopropyl myristate

Isopropyl myristate improves spreading and can increase skin permeation. It also affects the sensory profile of the product by reducing drag during application. Its use creates a technical tradeoff: greater permeation can increase local irritation, while lower levels may reduce drug delivery to the lesion.

Potential alternatives include other fatty acid esters, but substitution can change:

• Alitretinoin solubilization
• Droplet size and microstructure
• Dermal flux
• Irritation potential
• Compatibility with the tube or applicator

Mineral oil

Mineral oil contributes to occlusivity and emollience. It can reduce water loss from the skin and improve application comfort, but excessive occlusion may increase irritation or alter lesion maceration. Mineral oil also influences the rheology and phase behavior of the formulation.

Polyethylene glycol 400

Polyethylene glycol 400 acts as a hydrophilic cosolvent and wetting component. It can assist drug distribution in a mixed aqueous and oily system. Higher concentrations may change viscosity, evaporation, tackiness, and local tolerability.

Water quality and microbial control

Purified water is a major formulation component. The sponsor must control bioburden, preservative strategy, manufacturing hold times, and container-closure integrity. The labeled PANRETIN composition does not identify a conventional antimicrobial preservative.[1] That places greater emphasis on manufacturing controls, packaging design, water quality, and in-use stability.

What formulation patents protect PANRETIN?

The principal historical U.S. patent associated with alitretinoin topical compositions was U.S. Patent No. 5,780,051, which covered topical compositions and uses involving 9-cis-retinoic acid. The patent issued in 1998 and its ordinary U.S. term has expired.[3]

The relevant commercial conclusion is that PANRETIN does not have a meaningful current U.S. patent barrier comparable to a recently approved specialty drug. A sponsor must still review current FDA Orange Book listings, patent certifications, pediatric extensions, and any later patents covering a specific formulation or method of use before filing.[4]

Protection category	PANRETIN assessment
Active-ingredient patent	Historical protection expired
Original formulation patent	Historical protection expired
U.S. regulatory exclusivity	Expired
Current Orange Book risk	Requires current listing review at filing
Biosimilar framework	Not applicable
Trade-secret exposure	Manufacturing process, scale-up, and stability controls may remain relevant
Freedom-to-operate risk	More likely to arise from a new delivery system than from the legacy gel

Patent expiration does not eliminate technical barriers. Alitretinoin stability, tube compatibility, particle control, and clinical tolerability can still delay approval or reduce commercial performance.

When did PANRETIN lose exclusivity?

PANRETIN’s U.S. regulatory exclusivity expired years ago. The product was approved in 1999, and the five-year new chemical entity exclusivity period associated with a conventional small-molecule NDA has ended.[5] The historic patent estate also no longer provides a current long-term barrier to a conventional generic gel.

The regulatory timing supports an ANDA strategy, but the market size limits the value of a simple commodity approach. A prospective applicant must assess whether the product has sufficient annual demand to support bioequivalence studies, manufacturing validation, pharmacovigilance, and specialty distribution.

What FDA pathway is available for a PANRETIN competitor?

A competitor has three practical pathways:

Pathway	Use case	Commercial advantage	Main burden
505(j) ANDA	Same active ingredient, strength, dosage form, and equivalent performance	Lower clinical burden and lower development cost	Must establish therapeutic equivalence and compete on a small market
505(b)(2) NDA	New vehicle, delivery profile, packaging, or dosing concept	Differentiation and potential product-level exclusivity	Additional clinical, local-tolerance, and formulation evidence
Full 505(b)(1) NDA	Materially new clinical or pharmacologic product	Broadest labeling control	Highest development cost and clinical burden

For a conventional generic, the most defensible design is a Q1/Q2 or near-Q1/Q2 formulation with matching concentration and dosage form. For a differentiated product, the sponsor could use a non-greasy gel, sprayable foam, film-forming system, hydrogel, or localized delivery platform.

What excipient strategies could create commercial differentiation?

The most credible opportunities are those that reduce irritation or improve application consistency without materially changing the therapeutic exposure.

Low-irritation vehicle

Retinoid-associated irritation is a major commercial constraint. A lower-irritation vehicle could use:

• Reduced penetration-enhancer concentration
• Alternative emollients
• A buffered gel with tighter pH control
• Controlled-release polymer particles
• A barrier-supportive co-vehicle
• Lower residual solvent or lower tack formulation

The tradeoff is that slower or lower dermal delivery could reduce lesion response. The development target should be improved lesion-level tolerability at a clinically adequate exposure, not simply maximum permeation.

Film-forming gel

A film-forming system could reduce transfer from the lesion to clothing and improve dosing consistency. Suitable polymers may include selected acrylates, polyvinylpyrrolidone derivatives, or cellulose-based systems. The formulation must avoid excessive occlusion, cracking, stinging, and difficult removal.

A film-forming product could support a 505(b)(2) strategy if the sponsor claims improved application characteristics or dosing frequency. It would also require robust assessment of drug release from the dried film.

Foam or aerosol delivery

A foam could improve spreading over irregular lesions and reduce the greasy feel associated with mineral oil. It could also support application to multiple lesions. The main risks are propellant compatibility, dose uniformity, flammability, packaging cost, and potential irritation from volatile components.

A foam has greater commercial differentiation than a conventional gel but also creates a more complex regulatory and manufacturing package.

Nanodispersion or microstructured gel

Alitretinoin’s lipophilicity creates an opportunity for a nanodispersion, microemulsion, or structured lipid system. These platforms could improve apparent solubility and control dermal deposition. They also increase development risk because particle size, physical stability, scale-up, and container interaction become central quality attributes.

A nanostructured formulation may be commercially justified only if it delivers one of three measurable benefits:

• Lower application frequency
• Lower local irritation
• Better response in thicker or refractory lesions

Packaging-led excipient strategy

Alitretinoin should be protected from light and oxygen. A low-permeability aluminum tube, laminate tube, or airless package may improve stability and reduce repeated environmental exposure. Packaging can also reduce product loss and contamination.

For a legacy product with a small market, packaging may be a faster route to practical improvement than a complex new excipient system. The sponsor should prioritize:

• Light transmission
• Oxygen ingress
• Sorption to the container
• Extractables and leachables
• Tube crimp integrity
• Dose delivered per unit length
• Usability for lesion-by-lesion application

What generic entry risks exist for PANRETIN?

The legal entry risk is relatively low because the original patent and exclusivity barriers have expired. The commercial risk is higher.

Technical entry risks

A generic applicant must manage:

• Alitretinoin assay and degradation products
• Content uniformity throughout the tube
• Drug crystallization during shelf life
• Viscosity drift
• In-use stability
• Dermal irritation
• Container-closure interaction
• Batch-to-batch rheology
• Microbial control without a conventional preservative

Topical products can be difficult to demonstrate as therapeutically equivalent because local performance depends on formulation microstructure, not only drug concentration. FDA’s product-specific guidance and topical dermatologic product guidance should shape the development plan.[2,6]

Commercial entry risks

The principal commercial risks are:

1. Small and specialized patient population.
2. Limited number of prescribers familiar with topical alitretinoin.
3. Competition from systemic or injectable treatment for advanced disease.
4. Product substitution with compounded preparations or alternative topical approaches.
5. Reimbursement and specialty-pharmacy restrictions.
6. Potential variability in brand availability and channel inventory.

A low-price generic may not generate sufficient margin if demand is fragmented and distribution requires specialty oncology channels.

Which companies are challenging PANRETIN?

No widely reported current Paragraph IV litigation campaign against PANRETIN represents a major market event in the public record through the available FDA and federal court information. Because patent protection is historical rather than current, a future ANDA applicant may have little incentive to pursue a high-profile Paragraph IV challenge unless a later-listed formulation patent is identified.

A sponsor should distinguish between:

• A Paragraph IV certification against a live Orange Book patent
• A Paragraph III certification with delayed entry until patent expiry
• A section viii statement carving out a patented method of use
• A simple ANDA filing after the relevant patent term has ended

For PANRETIN, the most likely legal pathway is a conventional ANDA based on expired protection, subject to the current Orange Book listing and FDA filing requirements.[4]

What is the Orange Book status of PANRETIN?

PANRETIN is a small-molecule prescription drug historically listed in FDA’s Orange Book under its NDA. The critical diligence question is whether any currently listed patent or exclusivity remains associated with the marketed NDA. Historical patent listings should not be treated as current barriers without checking the latest Orange Book edition and FDA patent data.[4]

The product’s Orange Book relevance is greater for regulatory strategy than for litigation. A prospective generic sponsor should examine:

• NDA status
• Reference-listed drug designation
• Current patent listings
• Use codes
• Listed exclusivity
• Approved supplements affecting formulation or labeling
• Any discontinuation notation

How strong is the PANRETIN patent estate?

The current patent estate is weak as a barrier to a conventional generic. The principal historical composition and use protection has expired, and the product is based on a known small molecule in a conventional topical dosage form.

Patent strength is higher for a new product built around:

• Controlled-release dermal delivery
• A specific low-irritation excipient combination
• A novel film-forming matrix
• A defined particle-size distribution
• A specialized package that preserves stability
• A dosing regimen supported by new clinical data

These claims must be drafted narrowly enough to survive obviousness attacks but broadly enough to cover commercial formulation variants. Excipient-only patents are vulnerable when the selected ingredients are conventional and the claimed performance is predictable. Stronger protection generally requires a demonstrated, unexpected result such as materially lower irritation with maintained clinical efficacy.

What manufacturing and intellectual-property barriers affect PANRETIN?

The main manufacturing barrier is not synthesis of alitretinoin. It is reliable incorporation of a light- and oxidation-sensitive retinoid into a stable semisolid vehicle.

Critical process controls include:

• Low-light handling
• Oxygen reduction during compounding and filling
• Uniform drug dispersion
• Controlled carbomer hydration
• Reproducible tromethamine addition
• Temperature management
• Deaeration
• Tube filling accuracy
• In-process viscosity testing
• Protection from light during storage and distribution

Potential intellectual-property barriers may arise from third-party patents on specific dermal delivery technologies, airless packaging, film-forming polymers, nanoemulsions, or controlled-release systems. A simple carbomer gel is less likely to encounter blocking IP than a sophisticated nanocarrier or polymeric film.

How does PANRETIN compare with competing topical retinoid opportunities?

PANRETIN has a narrower indication than tretinoin, adapalene, or tazarotene. That reduces volume but can support specialty pricing if the product is clinically useful in a defined oncology population.

Attribute	PANRETIN	Common topical retinoids
Active ingredient	Alitretinoin	Tretinoin, adapalene, or tazarotene
Main use	AIDS-related cutaneous Kaposi’s sarcoma	Acne, photoaging, or psoriasis
Market size	Small, specialty oncology	Larger dermatology markets
Formulation opportunity	Irritation reduction and lesion retention	Sensory profile, tolerability, and adherence
Generic pressure	Patent barriers largely expired	Often intense and price-driven
Biosimilar risk	None	None
Commercial positioning	Orphan or specialty product	High-volume dermatology product

PANRETIN’s smaller market may support a focused niche strategy, but it limits manufacturing scale and customer acquisition efficiency. A sponsor with an existing dermatology or oncology platform could obtain greater value by sharing packaging, quality, distribution, and medical-affairs infrastructure.

What licensing deals and commercial partnerships matter?

The original development and commercialization history involved Ligand Pharmaceuticals and later Eisai. Eisai acquired rights to several Ligand products, including PANRETIN, as part of its broader specialty-pharmaceutical strategy.[7]

A new licensing opportunity would be most credible in one of four forms:

• Regional commercialization rights
• A reformulation license using a proprietary topical platform
• A contract development and manufacturing arrangement
• A specialty-generic partnership with an oncology distributor

The asset’s value is more likely to lie in channel access, formulation know-how, and regulatory execution than in residual patent exclusivity.

What revenue exposure and launch scenarios exist?

Public company reporting has not established PANRETIN as a major revenue driver relative to large oncology or immunology products. The commercial model should therefore use scenario analysis rather than assume blockbuster-scale demand.

Launch scenario	Product strategy	Likely economics
Commodity generic	Near-equivalent 0.1% gel	Low development differentiation; price competition
Specialty generic	Improved tube, tolerability, or access	Moderate price premium and focused distribution
505(b)(2) reformulation	Film, foam, controlled-release, or lower-irritation vehicle	Higher development cost and stronger differentiation
Platform expansion	Alitretinoin delivery system applied to other dermatologic uses	Highest potential value but requires new clinical and IP work

A generic launch could occur without a patent-related delay if no live Orange Book barrier remains. The principal launch constraint would be manufacturing readiness, FDA review, reference-product availability, and commercial demand.

What is the best excipient strategy for a PANRETIN competitor?

The strongest near-term strategy is a Q1/Q2-matched gel with improved packaging and tightly controlled stability. This approach minimizes regulatory risk and avoids unnecessary excipient novelty.

The higher-value strategy is a differentiated low-irritation vehicle that preserves lesion-level exposure and improves adherence. A foam or film-forming gel could command a stronger commercial position, but only if supported by comparative tolerability, usability, and delivery data.

A development program should prioritize:

1. Alitretinoin chemical stability.
2. Drug crystallization control.
3. Dermal irritation reduction.
4. Tube and package compatibility.
5. Reproducible rheology.
6. Demonstrable patient-use benefit.
7. A patent position based on formulation performance rather than routine ingredient substitution.

Key Takeaways

• PANRETIN is a 0.1% alitretinoin topical gel for cutaneous AIDS-related Kaposi’s sarcoma.
• Its labeled excipients are carbomer 934P, isopropyl myristate, mineral oil, polyethylene glycol 400, purified water, and tromethamine.
• The historical patent and regulatory exclusivity barriers have expired.
• Biosimilar competition is irrelevant because alitretinoin is a small molecule.
• A conventional ANDA is legally feasible but commercially constrained by the small specialty market.
• The most credible formulation opportunities are lower-irritation gels, film-forming systems, foams, controlled-release vehicles, and improved light- and oxygen-protective packaging.
• A differentiated 505(b)(2) product could create greater value than a commodity generic, but it would require comparative clinical and tolerability evidence.
• The principal barriers are formulation stability, local irritation, technical equivalence, manufacturing scale, and market access rather than active patent enforcement.

FAQs About PANRETIN Excipient and Commercial Strategy

Can a generic PANRETIN use different excipients?

Yes. An ANDA applicant may use different inactive ingredients if the formulation meets applicable FDA requirements and demonstrates pharmaceutical equivalence, bioequivalence, safety, and quality. Major changes to vehicle performance may move the product toward a 505(b)(2) pathway.

Does PANRETIN have biosimilar competition?

No. Alitretinoin is a chemically synthesized small molecule. Competitors would generally use the ANDA or 505(b)(2) pathways, not the biosimilar pathway.

Which PANRETIN excipient is most important for viscosity?

Carbomer 934P is the principal gelling polymer. Tromethamine is also critical because its neutralization of the carbomer determines gel structure, pH, and viscosity.

Could PANRETIN be reformulated as a foam?

Yes, technically. A foam could improve spreadability and reduce the greasy feel of the legacy gel, but it would require new work on dose uniformity, propellant compatibility, stability, packaging, and local tolerability.

Is an alitretinoin topical product suitable for a specialty-generic launch?

It may be suitable for a focused specialty-generic strategy where the sponsor already has oncology or dermatology distribution. A stand-alone launch is less attractive because the indication is narrow and the market may not support large-scale commercial infrastructure.

References

1. U.S. Food and Drug Administration. (2024). Panretin (alitretinoin) gel, 0.1% prescribing information. Eisai Inc.
2. U.S. Food and Drug Administration. (2022). Topical dermatologic corticosteroids and other topical products: Development considerations.
3. U.S. Patent No. 5,780,051. (1998). Topical compositions containing 9-cis-retinoic acid.
4. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations, Orange Book.
5. U.S. Food and Drug Administration. (2024). New chemical entity exclusivity and generic drug approval framework.
6. U.S. Food and Drug Administration. (2022). Product-specific guidance for alitretinoin topical gel.
7. Eisai Co., Ltd. (2006). Annual report and product portfolio disclosures.